Visus Therapeutics to Host Its First Capital Markets Day Tomorrow

Visus Therapeutics will host its first Capital Markets Day for investors, analysts, and media tomorrow, August 31, 2021, from 10 am to 2 pm ET at Convene, 530 Fifth Avenue at 45th Street in New York City. During the Capital Markets Day, Ben Bergo, co-founder and chief executive officer; Rhett Schiffman, MD, MS, MHSA, co-founder, chief medical officer and head of …

Nova Eye Medical Acquires Glaucoma Treatment Patents from Dallas Company

Australian company Nova Eye Medical announced Aug. 26 that it had completed an acquisition of a patent portfolio related to ab interno trabeculotomy from Innovative Glaucoma Solutions, a surgeon-owned company in Dallas. Nova Eye, which maintains a US base in Fremont, California, paid US $2 million up front and 1.7 million in Nova Eye shares for the acquisition. Tom Spurling, managing director …

Artificial intelligence may accurately identify glaucoma medication bottles

Artificial intelligence has demonstrated the ability to differentiate bottles of ophthalmic medications and could feasibly function on a smartphone platform, according to a study published in Ophthalmology Glaucoma. Researchers pretrained seven convolutional neural network (CNN) models to classify five common ophthalmic medications using a set of 2,250 images captured by mobile phones. The two top-performing networks were included in separate iOS …

Topcon Healthcare, RetInSight to Partner on AI Technology

Topcon Healthcare reported Aug. 3 that it would integrate the retina AI technology of RetInSight GmbH, of Austria, into its OCT devices and Harmony cloud-based data management technology under a new partnership. Financial details were not disclosed. The Oakland, New Jersey, company, part of Tokyo-based Topcon Corporation, said the move was designed to lead to improved clinical decision making and …

Eyecelerator Innovation Forum Draws More than 500 Attendees

Industry, clinicians, and entrepreneurs who walked into Eyecelerator’s first in-person meeting were elated to be face to face, with jokes flying about Zoom dress codes and the lack of barking dogs during conversations. The business forum took place July 22 in conjunction with the 2021 meeting of the American Society of Cataract and Refractive Surgery at the Mandalay Bay Convention …

Regeneron Announces Topline Phase 2 Data of High-Dose Aflibercept in Wet AMD

Regeneron Pharmaceuticals announced that an ongoing phase 2 proof-of-concept trial evaluating an investigational 8 mg dose of aflibercept met its primary safety endpoint, with no new safety signals observed compared to the currently-approved 2 mg dose of Eylea (aflibercept) injection in patients with wet age-related macular degeneration (AMD). In this small trial involving 106 patients, a higher proportion of patients in the aflibercept …

Glaucoma Devices’ Expanding Role to Drive Double-Digit Market Growth

Glaucoma surgical devices will see increased use in all stages of disease and in stand-alone glaucoma procedures over the next 5 years, as companies commercialize more devices designed to meet these needs, according to a Market Scope report. Market Scope expects the glaucoma surgical device market to grow from nearly $800 million in 2021 to $1.7 billion in 2026, at …

Eyeque Announces Series C Closing With More Than $57 Million in Capital Raised

EyeQue announced that they have closed a Series C round and have raised more than $57 million in capital since the company was founded in 2015.  EyeQue aims to bring affordable vision correction with their smartphone vision tests. The company has developed a suite of at-home vision tests using optical smartphone attachments that consumers can use to self-administer a refractive …